search
Back to results

[18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients

Primary Purpose

Lung Cancer, Nonsmall Cell

Status
Enrolling by invitation
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
[18F]F-AraG Imaging
Sponsored by
University of California, Davis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Lung Cancer, Nonsmall Cell focused on measuring total body positron emission tomography

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Ability to understand the purposes and risks of the trial and has signed an IRB-approved informed consent form.
  3. Willingness and ability to comply with all protocol required procedures.
  4. For men and women of child-producing potential, willingness to use of effective double barrier contraceptive methods during the study, up to 1 day after the last administration of the investigational product.

    For NSCLC subjects only:

  5. Patients with histologically confirmed advanced, locally advanced, or localized NSCLC.
  6. Planned to undergo treatment with a PD-1 or PD-L1 inhibitor either as 1) monotherapy or as combination therapy with concurrent chemotherapy as treatment for advanced/metastatic disease; 2) As consolidation therapy following chemoradiation for locally advanced disease or 3) As induction therapy either as monotherapy or combination therapy with chemotherapy prior to planned surgical resection
  7. At least 1 tumor lesion > 1 cm (cannot be only in liver) documented on CT or MRI or FDG-PET/CT (RECIST criteria 1.1; >1.5 cm for nodal lesions) within 45 days prior to scan date.
  8. Per investigator's assessment and in consultation with oncologists, at least one eligible lesion must be sufficiently separated from tissues with known high [18F]F-AraG uptake, such as salivary glands, bladder, liver and kidneys so that quantification will be feasible.
  9. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  10. Meeting all clinical safety lab values per institution's standard of care, or Investigator's discretion, for patients receiving cancer treatment.

Exclusion Criteria:

Subjects are not eligible if they meet ANY of the following criteria:

  1. Serious comorbidities (nonmalignant disease or other conditions) that in the opinion of the investigator could compromise protocol objectives.
  2. History of recent COVID-19 infection within the last 2 months OR history of COVID requiring hospitalization with lung injury at Investigator's discretion
  3. Subjects with a diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the scan
  4. Subjects receiving therapy with nucleoside analogs including but not limited to: acyclovir, valaclovir, penciclovir, famciclovir, ganciclovir, ribavirin, valganciclovir, glanciclovir
  5. Pregnant women or nursing mothers.
  6. Body weight more than 240 kg (529 pounds)

    For NSCLC subjects only:

  7. Prior Treatment with anti-PD-1/PD-L1 immunotherapy.

    For Healthy subjects

  8. No primary care physician

Sites / Locations

  • UC Davis EXPLORER Molecular Imaging Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Healthy Volunteers

Non-Small Cell Lung Cancer Patients (NSCLC)

Arm Description

Study participants will undergo a single dynamic [18F]F-AraG PET/CT scan (of duration up to 90-minutes) on the uEXPLORER PET/CT scanner. There will be a follow-up visit or call 7 days after the scan to assess any adverse events that could be attributed to either the scan or the administration of [18F]F-AraG.

Study participants with NSCLC who are planned to receive PD-1/PD-L1 immunotherapy will undergo a pre-therapy dynamic [18F]F-AraG PET/CT scan, and an optional post-therapy (first dose only) dynamic [18F]F-AraG PET/CT scan on the uEXPLORER total-body scanner.

Outcomes

Primary Outcome Measures

Data on whole-body pharmacokinetics of [18F]F-AraG physiologic uptake in various healthy tissues
Data on [18F]F-AraG uptake in several tissue types will be collected from healthy subjects. This data will be presented in the form of time-activity curves (TAC) generated for each tissue type.
Data on whole-body pharmacokinetics of [18F]F-AraG pathologic uptake in tumor lesions relative to uptake in background tissues in NSCLC subjects
Data on [18F]F AraG uptake in tumor lesions and background activity in the same tissues as in Outcome 1 will be collected. This data will be similarly presented in the form of time-activity curves (TAC) generated for each tissue type, as well as for tumor lesions against their background tissues.
Develop recommendations for ideal time post [18F]F-AraG infusion to acquire static whole-body scans using standard PET scanners
Time-Activity Curves analysis of [18F]F-AraG uptake will provide insight into the earliest time to achieve adequate tumor versus non-malignant background tissue activity, as well as time to reach and remain in steady state up to 90 minutes.

Secondary Outcome Measures

Data on [18F]F-AraG uptake in advanced NSCLC before and after the first dose of PD-1/PD-L1 immunotherapy
For NSCLC subjects who undergo two [18F]F AraG PET/CT scans, the signal at a static time point post [18F]F-AraG infusion (obtained from the result of one of the outcome measures) from both scans will be observed for trends.

Full Information

First Posted
December 16, 2020
Last Updated
August 9, 2023
Sponsor
University of California, Davis
Collaborators
CellSight Technologies, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04678440
Brief Title
[18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients
Official Title
A Pilot Study of [18F]F-AraG Pharmacokinetics in Tumors and Non-Malignant Tissue Using Dynamic Total Body PET Imaging in Healthy Subjects and in Patients With Non-Small Cell Lung Cancer (NSCLC)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
March 31, 2021 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, Davis
Collaborators
CellSight Technologies, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
In this pilot study, healthy volunteers and patients with Non-Small Cell Lung Cancer will undergo [18F]F-AraG dynamic imaging on the uEXPLORER total body Positron Emission Tomography/Computerized Tomography scanner to obtain preliminary data regarding pharmacokinetics and early biodistribution images.
Detailed Description
[18F]F-AraG, a fluorine-18 labeled analog of an FDA approved drug (Nelarabine) is a new imaging tracer targeted at imaging activated T-cells. Given that immunotherapeutic strategies, in particular immune checkpoint antibodies, focus on the generation of T-cell-based antitumor immunity, uptake of [18F]F-AraG within the tumor is hypothesized to correlate with T-cell mediated immune response seen in the biopsy samples of cancer patients treated with immune checkpoint blockade. Correlation of pre- and post-treatment intratumoral immune infiltration by means of PET imaging will guide the development of future clinical trials investigating the role of [18F]F-AraG in the monitoring of anti-tumor immune responses. Therefore, proper quantification of [18F]F-AraG uptake in tumor lesions, and understanding its relation with physiologic uptake in background tissues is important. Note: checkpoint therapy in this study is standard-of-care and is not under investigation. Available PET/CT scanners can obtain dynamic images only on a portion of the body as large as their axial field of view, generally anywhere between 15-30 cm. The 194 cm long uEXPLORER total-body PET scanner is the world's first device to offer the ability to tomographically image all parts of the body simultaneously. Thus, the uEXPLORER PET/CT (now commercially available and with FDA 510(k) clearance) is the only scanner in the world capable of acquiring total-body dynamic images. In this pilot study, 2-4 healthy volunteers will undergo [18F]F-AraG dynamic imaging on the uEXPLORER total body PET/CT scanner to obtain preliminary data regarding pharmacokinetics and early biodistribution images. In addition, 2-4 patients with NSCLC and planned for standard-of-care PD-1/PD-L1 immunotherapy will undergo [18F]F-AraG dynamic imaging similarly on the uEXPLORER total body PET/CT scanner to obtain data regarding pharmacokinetics of the tracer in tumor lesions in the context of normal tissue uptake. An optional second similar scan will be performed 7-14 days after the first dose of immunotherapy to explore and document any treatment related changes in [18F]F-AraG uptake and kinetics. The study and data collected will be important to recommend an ideal time to acquire a whole body static scan using conventional and widely available PET/CT scanners for adequate tumor to background contrast and quantification, which in turn, will be essential for further clinical development of [18F]F-AraG to aid the monitoring of anti tumor immune responses.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Cancer, Nonsmall Cell
Keywords
total body positron emission tomography

7. Study Design

Primary Purpose
Basic Science
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Model Description
Healthy volunteers and patients with non-small cell lung cancer will undergo identical total-body PET scans. Lung cancer patients will undergo an additional PET scans after starting treatment.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
8 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Healthy Volunteers
Arm Type
Experimental
Arm Description
Study participants will undergo a single dynamic [18F]F-AraG PET/CT scan (of duration up to 90-minutes) on the uEXPLORER PET/CT scanner. There will be a follow-up visit or call 7 days after the scan to assess any adverse events that could be attributed to either the scan or the administration of [18F]F-AraG.
Arm Title
Non-Small Cell Lung Cancer Patients (NSCLC)
Arm Type
Experimental
Arm Description
Study participants with NSCLC who are planned to receive PD-1/PD-L1 immunotherapy will undergo a pre-therapy dynamic [18F]F-AraG PET/CT scan, and an optional post-therapy (first dose only) dynamic [18F]F-AraG PET/CT scan on the uEXPLORER total-body scanner.
Intervention Type
Drug
Intervention Name(s)
[18F]F-AraG Imaging
Intervention Description
Total body PET imaging using [18F]F-AraG
Primary Outcome Measure Information:
Title
Data on whole-body pharmacokinetics of [18F]F-AraG physiologic uptake in various healthy tissues
Description
Data on [18F]F-AraG uptake in several tissue types will be collected from healthy subjects. This data will be presented in the form of time-activity curves (TAC) generated for each tissue type.
Time Frame
Baseline
Title
Data on whole-body pharmacokinetics of [18F]F-AraG pathologic uptake in tumor lesions relative to uptake in background tissues in NSCLC subjects
Description
Data on [18F]F AraG uptake in tumor lesions and background activity in the same tissues as in Outcome 1 will be collected. This data will be similarly presented in the form of time-activity curves (TAC) generated for each tissue type, as well as for tumor lesions against their background tissues.
Time Frame
Baseline and 7-14 days after first dose of PD-1/PD-L1
Title
Develop recommendations for ideal time post [18F]F-AraG infusion to acquire static whole-body scans using standard PET scanners
Description
Time-Activity Curves analysis of [18F]F-AraG uptake will provide insight into the earliest time to achieve adequate tumor versus non-malignant background tissue activity, as well as time to reach and remain in steady state up to 90 minutes.
Time Frame
Baseline and 7-14 days after first dose of PD-1/PD-L1
Secondary Outcome Measure Information:
Title
Data on [18F]F-AraG uptake in advanced NSCLC before and after the first dose of PD-1/PD-L1 immunotherapy
Description
For NSCLC subjects who undergo two [18F]F AraG PET/CT scans, the signal at a static time point post [18F]F-AraG infusion (obtained from the result of one of the outcome measures) from both scans will be observed for trends.
Time Frame
Baseline and 7-14 days after first dose of PD-1/PD-L1

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years. Ability to understand the purposes and risks of the trial and has signed an IRB-approved informed consent form. Willingness and ability to comply with all protocol required procedures. For men and women of child-producing potential, willingness to use of effective double barrier contraceptive methods during the study, up to 1 day after the last administration of the investigational product. For NSCLC subjects only: Patients with histologically confirmed advanced, locally advanced, or localized NSCLC. Planned to undergo treatment with a PD-1 or PD-L1 inhibitor either as 1) monotherapy or as combination therapy with concurrent chemotherapy as treatment for advanced/metastatic disease; 2) As consolidation therapy following chemoradiation for locally advanced disease or 3) As induction therapy either as monotherapy or combination therapy with chemotherapy prior to planned surgical resection At least 1 tumor lesion > 1 cm (cannot be only in liver) documented on CT or MRI or FDG-PET/CT (RECIST criteria 1.1; >1.5 cm for nodal lesions) within 45 days prior to scan date. Per investigator's assessment and in consultation with oncologists, at least one eligible lesion must be sufficiently separated from tissues with known high [18F]F-AraG uptake, such as salivary glands, bladder, liver and kidneys so that quantification will be feasible. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 Meeting all clinical safety lab values per institution's standard of care, or Investigator's discretion, for patients receiving cancer treatment. Exclusion Criteria: Subjects are not eligible if they meet ANY of the following criteria: Serious comorbidities (nonmalignant disease or other conditions) that in the opinion of the investigator could compromise protocol objectives. History of recent COVID-19 infection within the last 2 months OR history of COVID requiring hospitalization with lung injury at Investigator's discretion Subjects with a diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the scan Subjects receiving therapy with nucleoside analogs including but not limited to: acyclovir, valaclovir, penciclovir, famciclovir, ganciclovir, ribavirin, valganciclovir, glanciclovir Pregnant women or nursing mothers. Body weight more than 240 kg (529 pounds) For NSCLC subjects only: Prior Treatment with anti-PD-1/PD-L1 immunotherapy. For Healthy subjects No primary care physician
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Simon R Cherry, PhD
Organizational Affiliation
UC Davis
Official's Role
Principal Investigator
Facility Information:
Facility Name
UC Davis EXPLORER Molecular Imaging Center
City
Sacramento
State/Province
California
ZIP/Postal Code
95816
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://studypages.com/s/a-total-body-pet-imaging-study-in-healthy-subjects-and-lung-cancer-patients-372396/
Description
Learn more or sign up for the study here!

Learn more about this trial

[18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients

We'll reach out to this number within 24 hrs